Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat

  • J Allergy Clin Immunol. 2016 Sep;138(3):934-936.e5. doi: 10.1016/j.jaci.2016.03.043.
Emel Aygören-Pürsün  1 ,  Markus Magerl  2 ,  Jochen Graff  3 ,  Inmaculada Martinez-Saguer  4 ,  Wolfhart Kreuz  4 ,  Hilary Longhurst  5 ,  Iman Nasr  5 ,  Murat Bas  6 ,  Ulrich Straßen  6 ,  Lei Fang  7 ,  Melanie Cornpropst  8 ,  Sylvia Dobo  8 ,  Phil Collis  8 ,  William P Sheridan  8 ,  Marcus Maurer  9
Affiliations
  • 1. Centre of Pediatrics III, Department of Hematology, Oncology and Hemostasis, Comprehensive Care Centre for Thrombosis and Hemostasis, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany.
  • 2. Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • 3. Institute of Clinical Pharmacology, Johann Wolfgang Goethe-University, Frankfurt, Germany.
  • 4. Haemophilia Centre Rhine Main, Frankfurt-Mörfelden, Germany.
  • 5. Department of Immunology, Barts Health NHS Trust, London, United Kingdom.
  • 6. HNO-Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
  • 7. Pharstat Inc, Durham, NC.
  • 8. BioCryst Pharmaceuticals Inc, Durham, NC.
  • 9. Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany. Electronic address: [email protected].
PMID: 27302552 DOI: 10.1016/j.jaci.2016.03.043
Products